New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma.

David H  Aggen

Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Seagen

Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign

Alejandro  Garcia

Employment - Adaptimmune

Jose M  Saro Suarez

No Relationships to Disclose

Amy  Sauer

Employment - Adaptimmune

Sebastiano  Cristiani

No Relationships to Disclose

Francine Elizabeth  Brophy

Employment - Adaptimmune

Stock and Other Ownership Interests  - Adaptimmune

Sharon  Streets

No Relationships to Disclose

Elliot  Norry

Employment - Adaptimmune

Leadership - Adaptimmune

Stock and Other Ownership Interests  - Adaptimmune

Ariel Ann  Nelson

Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst)

Travel, Accommodations, Expenses - Exelixis

Other Relationship - Merck Sharp & Dohme

Deepak  Kilari

Honoraria - Exelixis

Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Exelixis; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi

Speakers' Bureau - Astellas Pharma; AVEO; Exelixis; Janssen

Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen

Benjamin  Garmezy

Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Exelixis (Inst); Genentech (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kinnate Biopharma (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenshine (Inst)

(OPTIONAL) Uncompensated Relationships - Amgen (Inst); AVEO (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Sanofi (Inst)

John A.  Charlson

Consulting or Advisory Role - Adaptimmune; Deciphera

Research Funding - Lilly (Inst)

Jon  Zugazagoitia

Honoraria - AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Roche/Genentech; Sanofi/Regeneron

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron

Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Roche

Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Roche/Genentech

Emiliano  Calvo

Employment - HM Hospitales; START

Leadership - BeiGene; European Organisation for Research and Treatment of Cancer (EORTC); Merus NV; Novartis; PharmaMar; Sanofi; START

Stock and Other Ownership Interests  - Oncoart Associated; START

Honoraria - HM Hospitales

Consulting or Advisory Role - Adcendo; Amunix; Anaveon; AstraZeneca/MedImmune; Bristol-Myers Squibb; Chugai Pharma; Diaccurate; Elevation Oncology; Ellipses Pharma; Genmab; Janssen-Cilag; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; Roche/Genentech; Servier; Syneos Health; T-Knife; TargImmune Therapeutics

Research Funding - START

Other Relationship - CRIS Cancer Foundation; Foundation PharmaMar; Investigational Therapeutics in Oncological Sciences

Irene  Moreno

Consulting or Advisory Role - Ellipses Pharma; Exafield

Victor  Moreno

Employment - START

Consulting or Advisory Role - Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche

Speakers' Bureau - Bayer; Pierre Fabre

Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)

Expert Testimony - Medscape/Bayer; Nanobiotix

Travel, Accommodations, Expenses - Sanofi/Regeneron

Other Relationship - BMS

Christopher J.  Hoimes

Honoraria - Seagen

Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen

Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen

Research Funding - Alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); Nektar (Inst); NeoImmuneTech (Inst); Novartis (Inst); seagen (Inst)

(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)

David S.  Hong

Stock and Other Ownership Interests  - MolecularMatch; OncoResponse; Telperian

Consulting or Advisory Role - 28Bio; Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Exelixis; Experimental Drug Development Centre (EDDC)/A*STAR; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Incyte; Infinity Pharmaceuticals; Inhibrix Inc; Janssen; Jounce Therapeutics; Liberum; MedaCorp; Medscape; Novartis; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology

Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)

Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian

Andres  Cervantes

Consulting or Advisory Role - Amgen (Inst); Foundation Medicine (Inst); Merck Serono (Inst); Roche (Inst); Transgene (Inst)

Research Funding - Actuate Therapeutics (Inst); Adaptimmune (Inst); Amcure (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer (Inst); BeiGene (Inst); BMSi (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)

Other Relationship - Annals of Oncology; Cancer Treatment Reviews; ESMO Open